Clearmind Medicine Inc. - Common Shares (CMND) analyst actions
Rating and price-target actions on CMND in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CMND overview →
5 measured CMND analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder | Press release | +0.97% | -1.74% | |
| Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites | Press release | -3.96% | -3.33% | |
| Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder | Press release | -2.97% | -4.63% | |
| Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients | Press release | -2.54% | +1.70% | |
| Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments | Press release | +1.64% | -4.69% |
Keep exploring
More CMND: earnings → · SEC filings → · CMND overview →